top of page



PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignance


Miller PG, Sperling AS, Mayerhofer C, McConkey M, Ellegast JM, Silva CD, Cohen DN, Wang C, Sharda A, Yan N, Saha S, Schluter C, Schechter IA, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaier K, Bhatt S, Lindsley RC, Ebert BL.

2023 Aug 18


BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Blood Advances

Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, Jain N, Garcia JS, Wong GC, Ooi M, Letai A, Konopleva M, Bhatt S.

2023 Jun 27;7(12):2917-2923.


Apoptosis, necrosis, and other forms of cell death

Reference Module in Biomedical Sciences

Mahesh ANLim NSE, Wong MH, Ray SD, Bhatt S

2023 Jun 23


Cytochrome P450

Reference Module in Biomedical Sciences

Bhatia KS, Mahesh AN, Bhatt S.

2023 Mar 8


Cell Cycle

Reference Module in Biomedical Sciences

Mahesh AN, Bhatia KS, Bhatt S.

2023 Jan 4


CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response


Jutzi JS, Marneth AE, Jiménez-Santos MJ, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, Pozdnyakova O, van Galen P, Al-Shahrour F, Nam AS, Mullally A.

2022 Dec;37(2):359-369.


Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.


Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC.
2022 Apr;36(4):1088-1101​


Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma,


Adamia S, Chyra Z, O'Keefe M, Bhatt S, Wen K, Fell G, Tai YT, Letai A, Abiatari I, Dorfman D, Hideshima T, Anderson K. 

2021 November;138, Supplement 1, 2021, Page 2688.


Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse model

Star Protocols

Olesinski EA, Bhatt S.

2021 May 12;2(2):100461


Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-

Journal of Biomolecular Structure and Dynamics

Dey SK, Saini M, Dhembla C, Bhatt S, Rajesh AS, Anand V, Das HK, Kundu S


Cover_Cell Press Cancer Cell.jpg

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. 

Cancer Cell

Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint AJ, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. 

2020 Dec 14;38(6):872-890.e6

A JHem.cover.gif

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.

American Journal of Hematology

Garcia JS*, Bhatt S*, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A. 

2020 Mar;95(3):245-250.

blood jul 2019.png

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. 


Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL. 

2019 Jul 11;134(2):160-170.


Statins enhance efficacy of venetoclax in blood cancers. 

Science Translational Medicine

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. 

2018 Jun 13;10(445).


PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.

Blood (In press)

Miller PG, Sperling AS, Mayerhoffer C, McConkey ME, Elegast J, Silva CD, Wang C, Cohen DN, Sharda A, Yan N, Saha S, Schluter C, Schechter I, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaeir K, Bhatt S, Lindsley RC, Ebert BL. 

nat chem bio 13.png

Inhibition of USP10 induces degradation of oncogenic FLT3. 

Nature Chemical Biology

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

2017 Dec;13(12):1207-1215.

Cover_ASH Blood.PNG

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. 


Bhatt S*, Parvin S*, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS. 

2017 Apr 20;129(16):2246-2256.

Cover_Leukemia and Lymphoma.jpg

Interleukin 21 - its potential role in the therapy of B-cell lymphomas. 

Leukemia & Lymphoma

Bhatt S, Sarosiek KA, Lossos IS. 

2017 Jan;58(1):17-29.


Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. 


Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, Verdun R, Gray NS, Lossos IS. 

2016 Jul 14;128(2):239-48.


miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. 


Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS. 

2016 Jun 9;127(23):2856-66.

Cover_ASH Blood Volume 126 Issue 13.png

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. 


Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. 

2015 Sep 24;126(13):1555-64.

leukemia jul 2015.png

Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. 


Zhu D*, Bhatt S*, Lu X, Guo F, Veelken H, Hsu DK, Liu FT, Alvarez Cubela S, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos IS. 

2015 Jul;29(7):1587-99.

Cover_ASH Blood Volume 122, Issue 7.png

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. 


Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, Mesri EA, Lossos IS. 

2013 Aug 15;122(7):1233-42.

Cover_JCI Volume 123, Issue 6.jpg

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. 

Journal of Clinical Investigation

Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos JC. 

2013 Jun;123(6):2616-28.

pnas 2010 jul.jpg

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. 

Proceedings of the National Academy of Sciences of the United States of America

Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS. 

2010 Jul 20;107(29):13069-74.

bottom of page